Evidence map›Paper›PMID 36627789›Full record

ArticleCurrent drug metabolism2022

Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery.

Benu Chaudhary, Parveen Kumar, Preeti Arya, Deepak Singla, Virender Kumar, Davinder Kumar, Roshan S, Sheetu Wadhwa, Monica Gulati, Sachin Kumar Singh and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Benu ChaudharyDepartment of Pharmacology, Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India.
Parveen KumarDepartment of Life Science, Shri Ram College of Pharmacy, Karnal, Haryana, India.
Preeti AryaDepartment of Pharmacology, Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India.
Deepak SinglaDepartment of Pharmacology, Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India.
Virender KumarDepartment of Pharmacology, Swami Dayanand Post Graduate Institute of Pharmaceutical Sciences, Rohtak, Haryana, India.
Davinder KumarDepartment of Pharmacology, Swami Dayanand Post Graduate Institute of Pharmaceutical Sciences, Rohtak, Haryana, India.
Roshan SDepartment of Pharmacology, Deccan School of Pharmacy, Hyderabad, India.
Sheetu WadhwaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Monica GulatiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Sachin Kumar SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Kamal DuaFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India.
Madan Mohan GuptaFaculty of Medical Sciences, School of Pharmacy, The University of the West Indies, St. Augustine, Trinidad & Tobago, West Indies.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is characterized by disrupted molecular variables caused by cells that deviate from regular signal transduction. The uncontrolled segment of such cancerous cells annihilates most of the tissues that contact them. Gene therapy, immunotherapy, and nanotechnology advancements have resulted in novel strategies for anticancer drug delivery. Furthermore, diverse dispersion of nanoparticles in normal stroma cells adversely affects the healthy cells and disrupts the crosstalk of tumour stroma. It can contribute to cancer cell progression inhibition and, conversely, to acquired resistance, enabling cancer cell metastasis and proliferation. The tumour's microenvironment is critical in controlling the dispersion and physiological activities of nano-chemotherapeutics which is one of the targeted drug therapy. As it is one of the methods of treating cancer that involves the use of medications or other substances to specifically target and kill off certain subsets of malignant cells. A targeted therapy may be administered alone or in addition to more conventional methods of care like surgery, chemotherapy, or radiation treatment. The tumour microenvironment, stromatogenesis, barriers and advancement in the drug delivery system across tumour tissue are summarised in this review.

Indexed as

drug deliverygene therapyimmunotherapynanoparticlesproliferation.Tumor microenvironment

Identifiers

PMID36627789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.